Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications
Acute myeloid leukemias (AMLs) comprise a group of genetically heterogeneous hematological malignancies that result in the abnormal growth of leukemic cells and halt the maturation process of normal hematopoietic stem cells. Despite using molecular and cytogenetic risk classification to guide treatm...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/202 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588999254867968 |
|---|---|
| author | Shaimaa Khattab Adriatik Berisha Natalia Baran Pier Paolo Piccaluga |
| author_facet | Shaimaa Khattab Adriatik Berisha Natalia Baran Pier Paolo Piccaluga |
| author_sort | Shaimaa Khattab |
| collection | DOAJ |
| description | Acute myeloid leukemias (AMLs) comprise a group of genetically heterogeneous hematological malignancies that result in the abnormal growth of leukemic cells and halt the maturation process of normal hematopoietic stem cells. Despite using molecular and cytogenetic risk classification to guide treatment decisions, most AML patients survive for less than five years. A deeper comprehension of the disease’s biology and the use of new, targeted therapy approaches could potentially increase cure rates. <i>RAS</i> oncogene mutations are common in AML patients, being observed in about 15–20% of AML cases. Despite extensive efforts to find targeted therapy for <i>RAS</i>-mutated AMLs, no effective and tolerable RAS inhibitor has received approval for use against AMLs. The frequency of <i>RAS</i> mutations increases in the context of AMLs’ chemoresistance; thus, novel anti-RAS strategies to overcome drug resistance and improve patients’ therapy responses and overall survival are the need of the hour. In this article, we aim to update the current knowledge on the role of RAS mutations and anti-RAS strategies in AML treatments. |
| format | Article |
| id | doaj-art-ab4933d68fb34302b99befbfbb5e060f |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-ab4933d68fb34302b99befbfbb5e060f2025-01-24T13:24:22ZengMDPI AGBiomedicines2227-90592025-01-0113120210.3390/biomedicines13010202Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical ImplicationsShaimaa Khattab0Adriatik Berisha1Natalia Baran2Pier Paolo Piccaluga3Biobank of Research, IRCCS Azienda Ospedaliera, Universitaria di Bologna, Policlinico di S. Orsola, 40138 Bologna, ItalyDivision of Hematology, University of Pristina, 10000 Pristina, KosovoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USABiobank of Research, IRCCS Azienda Ospedaliera, Universitaria di Bologna, Policlinico di S. Orsola, 40138 Bologna, ItalyAcute myeloid leukemias (AMLs) comprise a group of genetically heterogeneous hematological malignancies that result in the abnormal growth of leukemic cells and halt the maturation process of normal hematopoietic stem cells. Despite using molecular and cytogenetic risk classification to guide treatment decisions, most AML patients survive for less than five years. A deeper comprehension of the disease’s biology and the use of new, targeted therapy approaches could potentially increase cure rates. <i>RAS</i> oncogene mutations are common in AML patients, being observed in about 15–20% of AML cases. Despite extensive efforts to find targeted therapy for <i>RAS</i>-mutated AMLs, no effective and tolerable RAS inhibitor has received approval for use against AMLs. The frequency of <i>RAS</i> mutations increases in the context of AMLs’ chemoresistance; thus, novel anti-RAS strategies to overcome drug resistance and improve patients’ therapy responses and overall survival are the need of the hour. In this article, we aim to update the current knowledge on the role of RAS mutations and anti-RAS strategies in AML treatments.https://www.mdpi.com/2227-9059/13/1/202RASoncogeneAMLchemoresistanceRAF-MEK-ERK1/2RAS-like proteins |
| spellingShingle | Shaimaa Khattab Adriatik Berisha Natalia Baran Pier Paolo Piccaluga Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications Biomedicines RAS oncogene AML chemoresistance RAF-MEK-ERK1/2 RAS-like proteins |
| title | Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications |
| title_full | Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications |
| title_fullStr | Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications |
| title_full_unstemmed | Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications |
| title_short | Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications |
| title_sort | rat sarcoma virus family genes in acute myeloid leukemia pathogenetic and clinical implications |
| topic | RAS oncogene AML chemoresistance RAF-MEK-ERK1/2 RAS-like proteins |
| url | https://www.mdpi.com/2227-9059/13/1/202 |
| work_keys_str_mv | AT shaimaakhattab ratsarcomavirusfamilygenesinacutemyeloidleukemiapathogeneticandclinicalimplications AT adriatikberisha ratsarcomavirusfamilygenesinacutemyeloidleukemiapathogeneticandclinicalimplications AT nataliabaran ratsarcomavirusfamilygenesinacutemyeloidleukemiapathogeneticandclinicalimplications AT pierpaolopiccaluga ratsarcomavirusfamilygenesinacutemyeloidleukemiapathogeneticandclinicalimplications |